Study showcases KDM2B-PP1's role in enhancing recovery from facial nerve injury, suggesting therapeutic potential.
KDM2B-PP1 is a novel epigenetic modulator that selectively promotes SC-mediated remyelination and functional recovery after peripheral nerve injury. These findings provide new insight into the epigenetic regulation of peripheral nerve regeneration and support KDM2B-PP1 as a potential therapeutic candidate for PNI.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: